Typhoid Conjugate Vaccine

Active immunization against Typhoid infection

Adults aged <45 years. Intramuscular A single 0.5 mL IM dose

Infants, children, and adolescents aged >6 months. Intramuscular A single 0.5 mL IM dose

The vaccine should be administered intramuscularly in the deltoid muscle of the upper arm if muscle mass is adequate for children 2 years and above, adolescents and adults. For infants and toddlers aged >6 months to <2 years of age, the vaccine should be administered intramuscularly in the vastus lateralis muscle on anterolateral aspect of thigh. This vaccine should not be injected into the gluteal area or in any areas where there may be a nerve trunk.

Hypersensitivity to any component of the vaccine Pregnant & lactating women In case of fever and severe infection

Do not administer intravenously, intradermally or subcutaneously. Typhoid Conjugate Vaccine protects against typhoid fever caused by Salmonella typhi. Protection is not conferred against Salmonella paratyphi and other non typhoidal Salmonellae.

Not Classi Safety and effectiveness have not been established in pregnant women and in nursing mothers. It is not known whether the vaccine is excreted in human milk.

The most frequently reported local adverse events after administration of Typhoid Conjugate Vaccine were Injection Site Pain (4.50%), Injection Site erythema (0.64%) and Injection site Swelling (0.32%). These usually occurred within first 48 hours and disappeared within 2-3 days. The most frequently reported systemic adverse events were Pyrexia (2.25%), Vomiting (0.96%), Headache (0.64%), Fatigue (0.64%), Arthralgia (0.32%) and Rash (0.32%). No vaccine-related serious adverse events (SAEs) were reported in the clinical trial.

Typhoid Vi Conjugate Vaccine is a clear, colorless solution, free from visible particulate matter. The vaccine contains 25 mcg of Typhoid Vi polysaccharide conjugated to CRMt97. The polysaccharide is manufactured using Citrobacter freundii sensu lato 3056 (Vi) and is conjugated to CRM197 as a carrier protein. Sodium Chloride and Phosphate Buffer are used as a diluent (buffering agent) in vaccine formulation. 2-Phenoxyethanol is added as a preservative.